drugset / Trial / NCT05432492
A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase II open label, multicenter study to evaluate the efficacy and safety of AK112 (PD-1/VEGF Bispecific) in patients with unresectable hepatocellular carcinoma (HCC).
Timeline
- Start
- 2022-08-03
- Primary completion
- 2025-04-30
- Completion
- 2025-06-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivonescimab | Monoclonal antibody | — | Intravenous |